## Kevin Mills

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7546384/publications.pdf Version: 2024-02-01



KEVIN MULS

#	Article	IF	CITATIONS
1	Ageing, age-related diseases and oxidative stress: What to do next?. Ageing Research Reviews, 2020, 57, 100982.	10.9	321
2	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Molecular Neurodegeneration, 2016, 11, 3.	10.8	236
3	Reproducibility of Molecular Phenotypes after Long-Term Differentiation toÂHuman iPSC-Derived Neurons: A Multi-Site Omics Study. Stem Cell Reports, 2018, 11, 897-911.	4.8	135
4	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	10.8	121
5	†The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research, 2020, 9, 1349.	1.6	116
6	Lamin and the heart. Heart, 2018, 104, 468-479.	2.9	113
7	â€~The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research, 2020, 9, 1349.	1.6	95
8	Identification of novel bile acids as biomarkers for the early diagnosis of Niemannâ€Pick C disease. FEBS Letters, 2016, 590, 1651-1662.	2.8	82
9	The Identification of New Biomarkers for Identifying and Monitoring Kidney Disease and Their Translation into a Rapid Mass Spectrometry-Based Test: Evidence of Presymptomatic Kidney Disease in Pediatric Fabry and Type-I Diabetic Patients. Journal of Proteome Research, 2013, 12, 2013-2021.	3.7	63
10	Regulation of post-Golgi LH3 trafficking is essential for collagen homeostasis. Nature Communications, 2016, 7, 12111.	12.8	54
11	Identification of α1-Antitrypsin Variants in Plasma with the Use of Proteomic Technology. Clinical Chemistry, 2001, 47, 2012-2022.	3.2	52
12	New Role for LEKTI in Skin Barrier Formation: Label-Free Quantitative Proteomic Identification of Caspase 14 as a Novel Target for the Protease Inhibitor LEKTI. Journal of Proteome Research, 2010, 9, 4289-4294.	3.7	41
13	iPSC-derived neuronal models of PANK2-associated neurodegeneration reveal mitochondrial dysfunction contributing to early disease. PLoS ONE, 2017, 12, e0184104.	2.5	39
14	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e001974.	3.6	38
15	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, .	3.6	34
16	Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning. Molecular and Cellular Proteomics, 2020, 19, 114-127.	3.8	32
17	The embryological basis of subclinical hypertrophic cardiomyopathy. Scientific Reports, 2016, 6, 27714.	3.3	29
18	The underglycosylation of plasma alpha1-antitrypsin in congenital disorders of glycosylation type I is not random. Glycobiology, 2003, 13, 73-85.	2.5	28

Kevin Mills

#	Article	IF	CITATIONS
19	Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease. Journal of Medical Genetics, 2020, 57, 38-47.	3.2	26
20	CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2018, 72, 171-176.	3.1	25
21	An LC–MS/MS-Based Method for the Quantification of Pyridox(am)ine 5′-Phosphate Oxidase Activity in Dried Blood Spots from Patients with Epilepsy. Analytical Chemistry, 2017, 89, 8892-8900.	6.5	24
22	Formate supplementation enhances folate-dependent nucleotide biosynthesis and prevents spina bifida in a mouse model of folic acid-resistant neural tube defects. Biochimie, 2016, 126, 63-70.	2.6	23
23	An optimised method for the proteomic profiling of full thickness human skin. Biological Procedures Online, 2016, 18, 15.	2.9	23
24	Proteomic Discovery and Development of a Multiplexed Targeted MRM-LC-MS/MS Assay for Urine Biomarkers of Extracellular Matrix Disruption in Mucopolysaccharidoses I, II, and VI. Analytical Chemistry, 2015, 87, 12238-12244.	6.5	20
25	The development of a peptide SRM-based tandem mass spectrometry assay for prenatal screening of Down syndrome. Journal of Proteomics, 2012, 75, 3248-3257.	2.4	17
26	Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165498.	3.8	17
27	Identification of new biomarkers for Down's syndrome in maternal plasma. Journal of Proteomics, 2012, 75, 2621-2628.	2.4	16
28	Urinary conjugated α-tocopheronolactone—a biomarker of oxidative stress in children with type 1 diabetes. Free Radical Biology and Medicine, 2013, 55, 54-62.	2.9	16
29	Multiplex High-Throughput Targeted Proteomic Assay To Identify Induced Pluripotent Stem Cells. Analytical Chemistry, 2017, 89, 2440-2448.	6.5	15
30	A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project. Mechanisms of Ageing and Development, 2021, 194, 111426.	4.6	14
31	Current applications of biomarkers in cardiomyopathies. Expert Review of Cardiovascular Therapy, 2015, 13, 825-837.	1.5	13
32	Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2726-2735.	3.8	13
33	A novel method for the direct measurement of urinary conjugated metabolites of αâ€ŧocopherol and its use in diabetes. Molecular Nutrition and Food Research, 2010, 54, 599-600.	3.3	12
34	Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses. IScience, 2021, 24, 102020.	4.1	12
35	Free urinary glycosylated hydroxylysine as an indicator of altered collagen degradation in the mucopolysaccharidoses. Journal of Inherited Metabolic Disease, 2020, 43, 309-317.	3.6	10
36	An InÂVitro Whole-Organ Liver Engineering for Testing of Genetic Therapies. IScience, 2020, 23, 101808.	4.1	8

Kevin Mills

#	Article	IF	CITATIONS
37	Associations between Lifestyle Factors and Vitamin E Metabolites in the General Population. Antioxidants, 2020, 9, 1280.	5.1	8
38	Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report. BMC Nephrology, 2020, 21, 341.	1.8	6
39	Urinary oxidized, but not enzymatic vitamin E metabolites are inversely associated with measures of glucose homeostasis in middle-aged healthy individuals. Clinical Nutrition, 2021, 40, 4192-4200.	5.0	6
40	Niemann–Pick type C disease as proofâ€ofâ€concept for intelligent biomarker panel selection in neurometabolic disorders. Developmental Medicine and Child Neurology, 0, , .	2.1	6
41	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 2021, 10, 614.	1.6	4
42	Tissue Proteome of 2-Hydroxyacyl-CoA Lyase Deficient Mice Reveals Peroxisome Proliferation and Activation of ω-Oxidation. International Journal of Molecular Sciences, 2022, 23, 987.	4.1	4
43	An Optimized Method for the Proteomic Analysis of Low Volumes of Cell Culture Media and the Secretome: The Application and the Demonstration of Altered Protein Expression in iPSC-Derived Neuronal Cell Lines from Parkinson's Disease Patients. Journal of Proteome Research, 2019, 18, 1198-1207.	3.7	2
44	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. Journal of Visualized Experiments, 2016, , .	0.3	2
45	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 0, 10, 614.	1.6	2
46	Associations of metabolomic profiles with circulating vitamin E and urinary vitamin E metabolites in middle-aged individuals. Nutrition, 2022, 93, 111440.	2.4	1
47	Preparation of iPSCs for Targeted Proteomic Analysis. Methods in Molecular Biology, 2019, 1994, 131-139.	0.9	1